User profiles for J. Buscombe
John BuscombeUniversity of Pretoria Verified email at nhs.net Cited by 8948 |
Carcinoid tumour
ME Caplin, JR Buscombe, AJ Hilson, AL Jones… - The Lancet, 1998 - thelancet.com
Carcinoid tumours are often indolent asymptomatic tumours. However, a small but significant
proportion are malignant and difficult to manage. Multiple endocrine neoplasia type 1 (MEN…
proportion are malignant and difficult to manage. Multiple endocrine neoplasia type 1 (MEN…
Radioguided sentinel lymph node biopsy in breast cancer surgery
…, M Bagnasco, G Canavese, J Buscombe… - Journal of Nuclear …, 2001 - Soc Nuclear Med
The concept of sentinel lymph node biopsy in breast cancer surgery relates to the fact that
the tumor drains in a logical way through the lymphatic system, from the first to upper levels. …
the tumor drains in a logical way through the lymphatic system, from the first to upper levels. …
111In-and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial
I Virgolini, K Britton, J Buscombe, R Moncayo… - Seminars in nuclear …, 2002 - Elsevier
The high-level expression of somatostatin receptors (SSTR) on various tumor cells has
provided the molecular basis for successful use of radiolabeled peptide analogues as tumor …
provided the molecular basis for successful use of radiolabeled peptide analogues as tumor …
EANM/SNMMI guideline for 18F-FDG use in inflammation and infection
F Jamar, J Buscombe, A Chiti… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The aim of this guideline is to provide general information about performing 18F-FDG PET or
PET/CT in inflammation and infection. We provide evidence for efficacy where it is available…
PET/CT in inflammation and infection. We provide evidence for efficacy where it is available…
Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging
…, D Gopalan, TD Fryer, JR Buscombe… - Journal of the American …, 2017 - jacc.org
Background : Inflammation drives atherosclerotic plaque rupture. Although inflammation can
be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography (…
be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography (…
[HTML][HTML] Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a …
JB Cwikla, A Sankowski, N Seklecka, JR Buscombe… - Annals of …, 2010 - Elsevier
… Seklecka 2 , JR Buscombe 3 , A. Nasierowska-Guttmejer 4 , KG Jeziorski 2 5 , R.
Mikolajczak 6 , D. … Stepien 7 , J. Walecki 1 8 … JR Buscombe, ME Caplin, AJ Hilson …
Mikolajczak 6 , D. … Stepien 7 , J. Walecki 1 8 … JR Buscombe, ME Caplin, AJ Hilson …
[HTML][HTML] Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM …
…, F Jamar, O Israel, J Buscombe, J Martín-Comín… - European Journal of …, 2018 - Springer
Introduction Radiolabelled autologous white blood cells (WBC) scintigraphy is being
standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in …
standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in …
Bone scintigraphy: procedure guidelines for tumour imaging
…, RP Baum, A Bishof-Delaloye, J Buscombe… - European journal of …, 2003 - Springer
Aim The purpose of this document is to provide general information about bone scintigraphy
in oncology. These guidelines describe procedures currently in routine clinical use but …
in oncology. These guidelines describe procedures currently in routine clinical use but …
Sentinel node in breast cancer procedural guidelines
J Buscombe, G Paganelli, ZE Burak… - European journal of …, 2007 - Springer
Content Procedure guidelines for scintigraphic detection of sentinel node in breast cancer
are presented. Authors The paper was written by several experts in this field on behalf of the …
are presented. Authors The paper was written by several experts in this field on behalf of the …
Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors
JR Buscombe, ME Caplin… - Journal of Nuclear …, 2003 - Soc Nuclear Med
High-activity 111 In-pentetreotide has been used to treat patients with disseminated
neuroendocrine tumors. There is, however, little information related to the efficacy of this agent …
neuroendocrine tumors. There is, however, little information related to the efficacy of this agent …